Analyseberichte - TradeFomo

Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

All AAOI ABUS ABVX ACAD ACRV ADMA AGIO ALMS ALMU ALTS APGE ARTV ASX AUPH AVAV AVPT AXTI BCRX CAI CAKE CEG CELC CEP CGON CIEN CNC COGT CRCL CTMX CTRI DKNG DUOL FLUT GCT GLW GOOG GPCR HALO HCA HIMS HOOD HWM IDYA IREN IVVD KALA KALV KRYS LENZ LEVI LITE LQDA LRMR LULU LUNR MDGL MESO MIRM MOH MPWR MTCH MU MVST NBIS NKE NRIX NUE NVAX NXPI OKUR OLMA ONC ONTO ORKA OSCR PDFS PHAT POET PRLD PYG RBLX RDDT RIGL RKLB SGHC SPRY SRPT TARS TBPH TH TRVI TSHA TTMI UNH VEON VOR WVE XFOR ZBIO ZLAB ZYME

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.

Cogent Biosciences (COGT): The 500% Miracle Drug and the Smart Money's Quiet Exit

2026-04-01BearishStrongChange from report: -12.0%1M: +3.9%3M: +9.2%

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.